42 completed, 9 unknown, 8 terminated, 6 recruiting. 78 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 78 | Completed 42, Unknown 9, Terminated 8, Recruiting 6, Withdrawn 6, Active not recruiting 4, Not yet recruiting 3 |
Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| Statins to Prevent Cancer Associated Blood Clots Rosuvastatin, Placebo Drug - Venous Thromboembolism, Cancer | Phase 4 | Recruiting | Brigham and Women's Hospital | 4000 | 2026-06-11 | 2026-09-16 |
| inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT Short duration prophylaxis, Higher intensity and longer duration prophylaxis, Control - Venous Thromboembolism, Venous Thromboses | Phase 4 | Recruiting | Leiden University Medical Center | 10078 | 2024-11-11 | 2026-09-08 |
| Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial Apixaban 2.5 MG - Venous Thromboembolism, Bleeding | Phase 4 | Recruiting | Clinical Urology and Epidemiology Working Group | 5436 | 2024-06-06 | 2025-05-28 |
| Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital Initial Heparin Dose Modification - Pulmonary Embolism, Deep Vein Thrombosis | Phase 4 | Active not recruiting | Inova Health Care Services | 145 | 2023-09-20 | 2025-11-26 |
| Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk Rivaroxaban group - Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 550 | 2023-04-05 | 2023-03-28 |
| The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Active not recruiting | Herlev and Gentofte Hospital | 5000 | 2023-04-01 | 2025-05-15 |
| What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? 30-day DAPT, Guideline-directed therapy - Acute Coronary Syndrome, Myocardial Infarction | Phase 4 | Recruiting | St. Antonius Hospital | 2000 | 2023-01-11 | 2023-12-15 |
| Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism Thrombolytic, Standard anticoagulation - Pulmonary Embolism | Phase 4 | Completed | Faculty Hospital Kralovske Vinohrady | 558 | 2022-10-19 | 2026-11-06 |
| Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism Anticoagulation with heparin, EkoSonicTM Endovascular System - Pulmonary Embolism | Phase 4 | Active not recruiting | Boston Scientific Corporation | 544 | 2021-08-02 | 2026-07-01 |
| Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study Receipt of enoxaparin, Placebo - Venous Thromboembolism, Bleeding as Surgical Complication (Treatment) | Phase 4 | Withdrawn | University of Utah | 2021-07-01 | 2021-10-08 | |
| Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Apixaban 2.5 MG, Placebo oral tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | Brigham and Women's Hospital | 600 | 2021-03-01 | 2025-11-14 |
| Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test. Standard Enoxaparin 40 mg once-daily before randomization, Standard Enoxaparin 40 mg once-daily after randomization, Escalated Enoxaparin 30 mg twice-daily after randomization - Venous Thromboembolism | Phase 4 | Terminated | Pirogov Russian National Research Medical University | 9 | 2021-03-01 | 2025-01-07 |
| Pre- Vs Postoperative Thromboprophylaxis for Liver Resection enoxaparin or tinzaparin or dalteparin, No intervention - Liver Cancer, Surgery | Phase 4 | Recruiting | Helsinki University Central Hospital | 1012 | 2021-02-10 | 2025-02-14 |
| Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism TNKase, Placebo, Enoxaparin - Pulmonary Embolism, COVID | Phase 4 | Terminated | Cedars-Sinai Medical Center | 2 | 2020-09-08 | 2021-10-26 |
| Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism Rivaroxaban, Placebo - Pulmonary Embolism, Embolism | Phase 4 | Recruiting | Drahomir Aujesky | 276 | 2020-05-15 | 2026-05-22 |
| Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 Enoxaparin - COVID, Thrombosis | Phase 4 | Completed | Central Hospital, Nancy, France | 1000 | 2020-05-13 | 2023-08-07 |
| Screening for Cancer in Patients With Unprovoked VTE Fludeoxyglucose 18F - Venous Thromboembolic Disease, Respiratory Disease | Phase 4 | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 650 | 2019-10-23 | 2021-12-09 |
| Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism Alteplase, Unfractionated heparin, Placebo - Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism | Phase 4 | Terminated | Victor Tapson, MD | 4 | 2019-07-25 | 2021-06-11 |
Showing 20 of 78. Sign in to see all of them.
Pulmonary Embolism (69) · Venous Thrombosis (31) · Venous Thromboembolism (18) · Thrombosis (12) · Atrial Fibrillation (10) · Hemorrhage (6) · Stroke (6) · Thromboembolism (5) · Ventricular Dysfunction, Right (4) · Coronary Artery Disease (3) · Myocardial Infarction (3) · Atrial Flutter (2) · Cardiovascular Diseases (2) · Ischemia (2)
Embolism and Thrombosis (77) · Cardiovascular Diseases (76) · Vascular Diseases (76) · Respiratory Tract Diseases (68) · Lung Diseases (67) · Thrombosis (28) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Thromboembolism (18) · Heart Diseases (16) · Arrhythmias, Cardiac (10) · Brain Diseases (7) · Central Nervous System Diseases (7) · Cerebrovascular Disorders (7)
Tissue Plasminogen Activator (8) · Enoxaparin (7) · Heparin, Low-Molecular-Weight (7) · Rivaroxaban (7) · apixaban (7) · Dalteparin (6) · Heparin (5) · Warfarin (5) · Nadroparin (4) · Tinzaparin (4) · Aspirin (3) · Dabigatran (3) · Acetylcysteine (2) · Fibrinolytic Agents (2) · Phenprocoumon (2)
Beijing Chao Yang Hospital (5) · Boston Scientific Corporation (3) · Assistance Publique - Hôpitaux de Paris (2) · Brigham and Women's Hospital (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital (1) · Albert Einstein College of Medicine (1) · Alexandria University (1) · Azienda Ospedaliera Universitaria Policlinico (1) · Biotronik, Inc. (1) · Bracco Diagnostics, Inc (1) · Bristol-Myers Squibb (1) · British Thoracic Society (1) · Cantonal Hospital of St. Gallen (1) · Carlos III Health Institute (1)
United States (23) · France (11) · Germany (8) · China (7) · Netherlands (7) · Canada (6) · Spain (6) · Switzerland (5) · United Kingdom (5) · Finland (4) · Russia (4) · Australia (3) · Austria (3) · Belgium (3) · Denmark (3)
Aaron S Weinberg, MD (1) · Abdullah M Al-Rubaish, MD (1) · Alejandro Veres Racamonde, MD (1) · Amein K Al-Ali, PhD (1) · Azhar Supariwala, MD (1) · Aziz Sheikh, MD,FRCGP (1) · Banne Nemeth, dr (1) · Bob Smouse, MD (1) · Carol A Lambourne, PhD (1) · Chen Wang, PhD,MD (1) · Christopher J. Destache, Pharm. D. (1)
PMID 17065639, PMID 17289685, PMID 18656008, PMID 19741062, PMID 19853892, PMID 20040086, PMID 20352167, PMID 20353588, PMID 20553388, PMID 23299853, PMID 23306310, PMID 23489534, PMID 23812180, PMID 24135533, PMID 24643601, PMID 24768093, PMID 24807875, PMID 24876082, PMID 25900749, PMID 25903529, PMID 25908774, PMID 25919526, PMID 27411777, PMID 30025734, PMID 30352714, PMID 31643128, PMID 31926776, PMID 32444264, PMID 32493215, PMID 33337539, PMID 33444199, PMID 33502773, PMID 33779986, PMID 34363769, PMID 34530387, PMID 34622445, PMID 34878173, PMID 35244208, PMID 35381867, PMID 35588898, PMID 36303136, PMID 36354038, PMID 36695396, PMID 37350990, PMID 37977307, PMID 39007830, PMID 39971173, PMID 40888734, PMID 41057196, PMID 41910345
2023 (2), 2014 (1), 2016 (1), 2018 (1), 2019 (1), UG3HL176627 (1)